Clinical Trial Update: Asciminib Treatment Optimization in ≥ 3rd Line CML-CP [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating asciminib for treatment optimization in patients with chronic myeloid leukemia in chronic phase who are on ≥ third-line therapy has c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• SCEMBLIX (ASCIMINIB)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Chronic Myelogenous Leukemia | Phase 3 | Status: COMPLETED | Results posted: 2025-03-27